Glycated Hemoglobin and Prediabetes: A Systematic Review of HbA1c Thresholds for Type 2 Diabetes Prevention
Abstract
Background/Objectives: HbA1c is widely used to identify adults at increased risk of type 2 diabetes mellitus (T2DM), but major guidance differs on whether the lower limit of an HbA1c-defined risk range should be 5.7% (39 mmol/mol) or 6.0% (42 mmol/mol). This systematic review evaluated the prognostic and screening utility of HbA1c 5.7-6.4% compared with HbA1c 6.0-6.4% and examined whether available evidence supports threshold-based allocation of preventive interventions. Methods: The review was reported in accordance with PRISMA 2020 and registered in PROSPERO (CRD42019134344). PubMed/MEDLINE, Embase and the Cochrane Library were searched for studies published from 1 January 2016 to 1 January 2026. Eligible evidence comprised human studies in English, French, Hebrew, Italian or Spanish that evaluated HbA1c ranges below the diabetes diagnostic threshold in adults aged at least 40 years or younger adults with established risk factors. Two reviewers independently screened records and extracted data. Risk of bias was assessed using an adapted QUADAS-2 framework for threshold-performance evidence, supplemented by CASP-informed appraisal, and certainty was rated with GRADE domains. Narrative synthesis was selected because populations, thresholds, comparator tests, follow-up and outcome ascertainment were heterogeneous. Results: Seven studies were included. Evidence consistently supported a graded risk continuum rather than a single biological cut point. HbA1c 5.7-6.4% identifies…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.